Investigator Initiated Studies Program (Oncology)

From The Eisai U.S. Foundation

The Eisai USA Foundation, Inc. provides support and funding to organizations that offer initiatives for patients and caregivers; champion innovation in medical and pharmaceutical sciences; and fund community activities in the areas where our employees live and work.

Type of Support

Overview

Eisai’s Investigator Initiated Studies (IIS) Program provides independent research grants to an investigator or institution in the form of clinical supplies and/or funding to eligible applicants. IIS research grants must support scientifically compelling and innovative studies that are consistent with Eisai’s strategic research goals and therapeutic areas of focus and must address legitimate medical or scientific questions.

Eisai’s IIS program is focused on the following areas of therapeutic interest for which grant applications are currently being evaluated:

Oncology

  • Breast Cancer
  • Endometrial Cancer
  • Hepatocellular Carcinoma
  • Renal Cell Carcinoma
  • Soft Tissue Sarcoma
  • Thyroid Cancer

Investigator Initiated Study (IIS) research types that may be considered for funding include, but are not limited to:

  • Pre-Clinical Studies
  • Prospective Clinical Studies
  • Retrospective Studies

Eligibility

Organization's Location
USA
Program Location
USA
Organization Type
Individuals
Institutions

Ineligibility

FDA debarred /disqualified or federally excluded individuals and organizations or individuals or organizations with disciplinary action by any professional licensing body
Institutions who have been previously awarded IIS grants but who have not fulfilled their contractual obligations to Eisai
not specified

Submission

Required Attachments
Project Budget
Contact info
Review Criteria

The following factors are considered by the IIS Committee when determining whether a grant applicant is qualified to receive an IIS research grant:

  • Appropriate credentials, education and reputation (including valid medical license for Clinical IIS, lack of FDA debarment/disqualification and disciplinary action by a professional licensing body)
  • Demonstrated relevant experience, including publications in peer-reviewed journals and prior research
  • Clinical or research background, training and knowledge of disease or therapeutic area in which the research will be conducted
  • Ability and potential to successfully conduct the research for which the funds are requested (including staffing and site resources)
  • Ability to provide scientifically compelling and/or novel research to Eisai

Applications are evaluated based upon therapeutic area relevance and applicability, support of product or compound goals, scientifically compelling and innovative research that is congruent with the strategic focus for the product or compound in question, sound science, cost effectiveness and feasibility of proposal.

Learn more